Drug Delivery Resource Center

• › Articles (28)
• › White Papers (8)
• › News (43)
• › Products (23)

Product Spotlight: Newest DeltaV, a Sneak Peak
PharmaManufacturing.com
Ease of use, cybersecurity and batch management improvements are the focus of Emerson’s latest process control offering

Webcast: Serialization Strategies for Improving Supply Chain Security and Pedigree Compliance
PharmaManufacturing.com
Join industry experts from the California Board of Pharmacy, Procter & Gamble Pharmaceuticals and SAP for an insightful discussion on pedigree regulations and how companies are enabling an efficient and secure pharmaceutical supply chain to enhance patient safety and business value.

e-Pedigrees: Change During a Time of Uncertainty
PharmaManufacturing.com

A view of the future from Todd Applebaum, VP of Strategy and Operations Practice at Maxiom Group (www.maxiomgroup.com)

Podcast: Why California (Still) Matters
PharmaManufacturing.com
Don't assume that just because California has pushed back its pedigree/serialization compliance date back to 2015 that it doesn't matter anymore. It's still very relevant, says Pembroke Consulting's Adam Fein, and will likely serve as the model for inevitable federal regulations. Pharmaceutical Manufacturing spoke with Fein recently about these issues and the cost of compliance--this podcast picks up in the middle of the conversation.

[Editor's Note: For regular and truly expert insight on the pharma supply chain, visit Fein's Drug Channels blog.]

More Articles »

White Papers: In Depth Research

Residual Solvents by HT3 Headspace in Reference to USP 467 with a Comparison of Static Versus Dynamic Headspace Analysis
Author: Teledyne Tekmar
Posted: 09/22/2008
Residual solvents in pharmaceuticals are defined as volatile organic chemicals that are used or produced in the manufacture of drug substances, excipients or in the preparation of drug products. Because residual solvents do not provide therapeutic benefits, they should be removed, to the extent possible. Drug products should contain no higher levels of residual solvents than can be supported by safety data. Looking forward to the implementation of a revised USP 467 method, Teledyne Tekmar evaluated the new protocol, therefore this application will comply with the procedure and criteria changes set forth in the USP30 NF25, Second Supplement (effective December 1, 2007) and the interim revision announcement.

SAP Support of the Healthcare Supply Chain’s Ongoing Effort to Ensure Patient Safety and Drive Business Value
Author: SAP
Posted: 09/05/2008
This white paper provides a detailed look at SAP’s support for the Center for Healthcare Supply Chain Research Blueprint for Data Management & Data Sharing. It also offers a summary of the Blueprint concepts and a review short- and long-term business improvement opportunities that can be gained by leveraging EPCIS.

Nanoparticles in Pharmaceutical Manufacturing
Author: NETZSCH Fine Particle Technology, LLC
Posted: 04/14/2008
The paper explores the rapidly expanding role and significant performance advantages of nanoparticles in pharmaceutical applications. It provides an overview of nanoparticle uses in applications including diagnostic products, product packaging and biomarker discovery, as well as an extensive look at nanoparticle use in drug delivery. The paper also describes the ability to create nanoparticles efficiently and economically with media milling.

The Impact of Nanotechnology in Drug Delivery: Global Developments, Market Analysis, and Future Prospects
Author: NanoMarkets, LC
Posted: 11/01/2007
This report by NanoMarkets, LC includes an overview of nanoenabled drug delivery technologies, commercial applications and information on the companies pursuing them, information on nanotechnology initiatives and regulation in major international markets (North America, EU, Japan, Israel, etc.), as well as eight-year worldwide forecasts on the industry’s anticipated growth and timing thereof.

More White Papers »